Background: The structural limitations of currently available laser-cut nitinol stents in the highly diseased arterial system of the lower extremity are well described. These devices are frequently used in long-segment occlusions, at the adductor hiatus, and across the knee into the popliteal artery and tibial-peroneal trunk despite concerns related to the high mobility of the knee joint and the potential for external stent compression, fractures, and occlusion. The Supera stent (Abbott Vascular, Santa Clara, Calif) was developed to provide superior radial strength, fracture resistance, and flexibility compared with laser-cut nitinol stents. This study represents the initial U.S. experience in the management of lower extremity artery atherosclerotic disease with the Supera interwoven wire stent. Methods: Patients undergoing stent implantation in the 20-month period after the 2008 Food and Drug Administration clearance were included. Medical records, radiographic imaging, and procedural data were examined. Procedural angiograms were classified according to TransAtlantic Inter-Society Consensus criteria. Patency and limb loss rates were calculated using Kaplan-Meier analysis.
Advances in interventional devices have made it possible to traverse most occlusions of the femoralpopliteal region, achieving technical success in >95% of the cases in different series. [1] [2] [3] [4] [5] More than 20 years after the initial results with self-expanding metallic endoprostheses were reported, the technology still remains current as an accepted method to optimize patency of lower extremity endovascular interventions. 6 Stents offer acceptable midterm patency rates but fall short of being a long-term solution, particularly in the setting of complex lesions. 7 Current technology developed to minimize these shortcomings has resulted in new stent designs, new metal alloys, drug-eluting technology, and bioabsorbable structural support systems. 8, 9 The Supera (Abbott Vascular, Santa Clara, Calif) selfexpanding, interwoven, nitinol stent received Food and Drug Administration (FDA) approval for use in the femoropopliteal segment during 2014. The long-term results for treatment of lesions of the superficial femoral artery (SFA) in Leipzig, Germany, have been reported. 10 The purpose of this study was to retrospectively analyze clinical outcomes with use of the Supera stent in the management of femoral-popliteal artery atherosclerotic lesions in a population of severely diseased patients. This study represents the initial U.S. experience with stenting of the SFA using the Supera system.
METHODS
A prospective, single-center analysis of patients who underwent endovascular therapy for femoropopliteal From Preprocedural and postprocedural creatinine concentration and ankle-brachial index were recorded. Procedural characteristics were also recorded, including laterality, duration of intervention, fluoroscopy time, and iodinated contrast agent volume. Lesions were classified using the procedural angiograms according to the TransAtlantic Inter-Society Consensus II (TASC II) criteria (2007), type (stenosis or occlusion), length, and location (above the knee, below the knee, precisely at the knee, or extension into the tibial-peroneal trunk) of femoral-popliteal lesions. After completion of the procedure, all patients received at least 30 days of dual antiplatelet therapy (clopidogrel 75 mg daily and aspirin 81 mg daily). In those patients who had allergies, appropriate substitutions were advised. Loading doses of clopidogrel of 150 mg were given to all patients who were not taking the medication at the time of the procedure. All patients underwent physical examination, duplex ultrasound, and radiographic imaging during the clinical follow-up period. Significant restenosis was defined as >50% based on angiographic estimation or ultrasoundderived velocity parameters (peak systolic velocity ratio $ 2.0). Primary patency, assisted primary patency, secondary patency, restenosis, complication, and limb salvage rates were also calculated. Knee radiography was performed to assess stent integrity in the patients with extension into the distal femoral, popliteal, and tibial-peroneal arterial segment. Images were reviewed independently by one blinded radiologist and one vascular interventionalist. Renal dysfunction was defined as any elevation of creatinine levels, above 1.2 mg/dL, at any point before or after the stenting procedure. Chronic renal insufficiency was defined as renal dysfunction without the need for dialysis.
Statistical analysis. Demographic, safety, and efficacy data were summarized using descriptive statistics according to the data type. Qualitative and quantitative variables were calculated and presented.
Time-to-event rates were computed by the KaplanMeier method. The log-rank test assessed the potential impact of risk factors on outcome in the univariate setting. A multivariate Cox proportional hazard model analyzed the impact of potential risk factors and their interactions. Stent length and lesion length were intentionally kept in the model; other risk factors were eliminated using backwards selection. A P value of #.05 was assumed to show significance. All statistical analyses were performed and visualized using the Survival and ggplot2 packages in R.
11-13

RESULTS
Between February 2008 and December 2010, 147 consecutive cases of Supera stents placed in the femoralpopliteal segment were identified within the database. Two vascular surgeons at a single institution in a dedicated hybrid operative suite performed all procedures.
Demographic features. The mean age of the patients was 72 years (range, 45-94 years), with 75 men and 72 women in the cohort examined. The majority of patients, 76.2%, were white; 18.4% were Hispanic, 2.1% were African American, and 2.0% were Japanese. Left-sided lesions represented 51.7% of these cases. The demographic characteristics of our cohort are seen in Table I; Table II depicts their risk factors and comorbidities. Most patients were classified as American Society of Anesthesiologists class 3 ("patients with severe systemic disease").
Indications for intervention. Ischemic rest pain (38.1%) was the most common indication for intervention; 29.3% had tissue loss, 32.7% had claudication, and one patient (0.7%) was a case of acute-on-chronic limb ischemia. According to the Rutherford classification, about two-thirds of these patients were categorized as classes 4 to 6 (critical limb ischemia; Table III) .
Lesion characteristics. Forty-nine cases were classified as TASC D lesions, 41 were TASC C, 45 were system underwent a series of modifications (three generations) during the course of the study period, but there were no changes to the stent construct itself. In diameter, 154 stents were 5 mm, 78 were 6 mm, and 57 were 4 mm; the others are described in Table IV . The mean stent diameter was 5.9 mm, and the mean number of stents per patient was 1.76.
Procedural details. The average length of the procedures was 56:13 minutes (range, 00:21:01-122:02 minutes). Mean fluoroscopy time and iodinated contrast agent volume used were 18.86 minutes (range, 6-47.8 minutes) and 54.77 mL, respectively (range, 0-280 mL). The mean serum creatinine levels before and after intervention were 1.35 and 1.40 mg/dL, respectively (range, 0.4-7.5 and 0.4-9.2 mg/dL, respectively; Table IV). Of the 147 patients, 75 (51.02%) underwent a concomitant or prior adjuvant therapy in the treated extremity, other than angioplasty and stenting of the femoral-popliteal target lesion. Adjuvant therapy is defined as interventions involving the treated arterial segment before stenting or at different arterial segments proximal or distal to the target lesion in the ipsilateral extremity (Table V) . Follow-up. Clinical follow-up ranged from 0.2 to 33.7 months (mean, 12.7 months; median, 16 months). Duplex ultrasound and radiographic imaging follow-up spanned 0 to 26.8 months (mean, 8.4 months; median, 13 months).
Stent patency. Primary and assisted primary patency rates at 12 months were 89.8% and 91.2% based on Kaplan-Meier estimates (Figs 1 and 2) . The mean survival time was 1033.096 days (standard error of the mean, 46.56) in the primary patency group and 834.02 days (standard error of the mean, 54.61) in the assisted primary patency group.
Eighty-three patients in the cohort (56.5%) underwent a subsequent interventional or surgical procedure (minor amputation, débridement, or wound vacuum placement). Of this subgroup, 59 patients (71.1%) had interventional procedures; 33 of the 59 were target limb interventions, and 17 of these were study-stent related.
Of the 17 cases of stent-related reinterventions, 13 were performed to address restenotic nonocclusive lesions and 4 were performed for stent occlusions. Reinterventions for patients with stent occlusion resulted in an aggregate secondary patency rate of 93.2% at 12 months (Fig 3) . A total of seven patients underwent surgical bypass because of failure to achieve effective stent patency. One patient underwent distal bypass for extensive tissue loss despite having a patent stent secondary to diffuse severe tibial disease.
No statistically significant differences were noted when primary, assisted primary, or secondary patency rates were studied in relation to age, gender, laterality, race, Rutherford score, lesion location, TASC classification, or number of runoff vessels. Significant differences in the Cox hazard ratio (Table VI) were found for tissue loss (1.644; P < .05; 95% confidence interval [CI], 1.078-2.509) and medium lesion length (1.879; P < .01; 95% CI, 1.246-2.835), with a trend of long lesion length being almost significant (1.843; P < .05; 95% CI, 1.142-2.975). The Cox model also showed coronary artery disease to have a hazard ratio of 0.613 (P < .01; 95% CI, 0.432-0.869). An estimate of the Cox proportional hazards estimate over time for each of the significant risk factors is plotted in Fig 4. Stent integrity. Anterior-posterior and lateral knee radiography was performed in all patients with popliteal artery and tibial-peroneal artery extension (n ¼ 47 patients). There were no stent fractures identified with a mean interval to follow-up of 17.3 6 6.2 months. Routine radiography was then discontinued because of cost considerations and the absence of fracture in the popliteal subgroup. Limb loss. Eight patients suffered limb loss for a rate of 5.4% at latest follow-up. It is notable that five of the eight patients experiencing limb loss had patent stents at the time of amputation. Most of these patients had ongoing extensive bone infection leading to the amputation (n ¼ 5). The rest (n ¼ 3) had unreconstructable distal disease leading to worsening of wound condition and eventually amputation.
Morbidity. There were five readmissions within 30 days for target limb complications, which included instent occlusion, in-stent restenosis, extremity pain and pallor, peroneal artery rupture, and limb swelling. Twentythree readmissions were for clinical conditions not related to the treated extremity. Complications reported included cellulitis, elevated blood pressure, lifestyle-limiting claudication on the contralateral limb, amputation of the contralateral limb, congestive heart failure, pneumonia, neck pain, other peripheral vascular symptoms in the contralateral limb, renal failure, fever, diarrhea, urinary tract infection, dehydration, spine fracture, altered mental status, myocardial infarction, abscess, renal artery stenosis, central line infection, coronary artery disease, coagulopathy, ventricular tachycardia, shortness of breath, back pain, and renal insufficiency.
Mortality. There was no perioperative mortality, and 17 patients have died in the interval up to January 2013, resulting in a total mortality in this cohort of 11.6%.
DISCUSSION
The Supera stent is a self-expanding stent with six pairs of interwoven nitinol wires in a closed-cell configuration, a design that contributes to increased radial strength and compression-resistant conformability to biomechanical stress. Despite that critical limb ischemia is highly prevalent The primary and secondary patency rates at 12 months were calculated at 89.8% and 93.2%. Scheinert et al have a comparable data subset and found the 12-month primary and secondary patency rates to be 84.7% and 94.8%. 10 These patency rates are well above those previously published for non-drug-coated laser-cut self-expanding stents. In the Edwards Lifesciences Self-Expanding Stent Peripheral Vascular Disease Study (RESILIENT), the 1-year primary patency rate in much shorter lesions was 81.3%. 14 This registry represents a more anatomically complex subgroup of patients compared with the limited characteristics found in the Comparison of the Supera Peripheral System in the Superficial Femoral Artery (SUPERB) trial that led to the FDA approval of the device. Ninety patients (representing 61.2% of the total) had TASC C and D lesions. The mean lesion length was 184.51 mm and the mean stented length was 197.94 mm, which makes it one of the published series with the longest treated segments. Previous groups that published on specifically long SFA lesions had mean lesion lengths ranging from 139 to 160 mm, which negatively affected the patency rates of the analyzed stents. 15, 16 In the aftermath of the SUPERB trial, we came to better understand how elongation and compression affected patency rates, but this was something our group at the time was unaware of. We believe that this may have negatively affected our patency rate in the longer stented segments as is obvious on the Cox regression analysis in Fig 4. This has now been modified, and increased attention is put on vessel preparation before deployment.
As demonstrated in the Cox regression model, the presence of previous coronary artery disease resulted in better overall patency rates. Our current hypothesis as to the nature of this finding is the likelihood that this subgroup of patients had optimized cardiovascular medical therapy.
The hinge, torsion, and accessory flexion points of the SFA and popliteal artery are well described in the literature 17 and have led to high stent fracture rates. 18 Patients stented in this high mechanical strain group (popliteal and tibial-peroneal segment) were subselected and additionally evaluated with high-definition radiography. No fractures were found in all 47 patients of this subgroup at a mean follow-up of 17.32 6 6.2 months, which provides valuable data as to the durability and fracture-free life expectancy of this technology.
CONCLUSIONS
Stenting of the SFA and popliteal artery using the Supera stent system is safe and effective. The interwoven stent design may better serve areas under extreme mechanical stress. The nitinol wire form appears to demonstrate structural characteristics, biomechanical conformability, patency rates, and fracture-free life expectancy greater than those of other comparable platforms. Our results with this population of highly diseased patients are consistent with outcomes of the randomized controlled trial and other publications reporting the use of this device. 19 
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